Connect with us

Technology

Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets

Published

on

OSAKA, Japan, Feb. 20, 2024 /PRNewswire/ — Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has entered into a research collaboration agreement with InveniAI® LLC (Guilford, Connecticut, USA; President and CEO: Krishnan Nandabalan; “InveniAI”), to identify novel therapeutic targets by leveraging cutting-edge InveniAI’s artificial intelligence (AI) and machine learning (ML).

Under the terms of the agreement, InveniAI will identify novel therapeutic targets in multiple diseases specified by Ono by leveraging InveniAI’s AlphaMeld® and ChatAlphaMeldTM, its AI drug discovery platforms including cutting-edge technologies, such as powerful AI and ML algorithms and Generative AI tools, and propose drug discovery hypotheses for optimization. Ono will conduct validation studies to confirm the hypotheses for multiple therapeutic target candidates identified based on InveniAI’s drug discovery hypotheses. Ono will retain exclusive rights to develop and commercialize drug candidates generated through this collaboration worldwide.

“We appreciate InveniAI’s proprietary AI and ML technologies to identify drug discovery mechanisms utilizing comprehensively enormous amounts of data for the creation of innovative drugs,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research at Ono. “Through this collaboration, the efficiency of drug discovery research will be greatly improved, and we hope to provide innovative therapeutic options to patients worldwide.”

“InveniAI is thrilled to partner with Ono, a company renowned for its commitment to innovation in drug discovery and development. Our collaboration signifies the merging of our collective expertise and cutting-edge technologies aimed at expediting the identification of de-risked product opportunities,” said Krishnan Nandabalan, Ph.D., President and CEO at InveniAI, LLC. “Our unwavering commitment to enhancing patient outcomes drives us to consistently integrate technological innovation into our processes. A testament to this is our recent incorporation of large language modules, and generative AI culminating in the creation of ChatAlphaMeldä—a game-changing tool designed for the seamless utilization of advanced technology tools across the organization.”

About InveniAI® LLC:

Headquartered in Guilford, Conn., InveniAI® LLC stands as a global frontrunner in the application of AI and ML tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, InveniAI utilizes its cutting-edge AlphaMeld® platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company’s pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery.

For additional information, please visit https://www.inveniai.com/ | LinkedIn: @inveniai | Twitter: https://twitter.com/Inveni_AI

View original content to download multimedia:https://www.prnewswire.com/news-releases/ono-enters-into-a-research-collaboration-agreement-with-inveniai-to-identify-novel-therapeutic-targets-302066827.html

SOURCE Ono Pharmaceutical co., ltd.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Gamehaus Holdings Inc. to Announce Interim Financial Results for the First Nine Months of Fiscal 2025 on May 19, 2025

Published

on

By

SHANGHAI, May 15, 2025 /PRNewswire/ — Gamehaus Holdings Inc. (“Gamehaus” or the “Company”) (Nasdaq: GMHS), a technology-driven mobile game publisher, today announced that it will release its unaudited financial results for the first nine months of fiscal year 2025 ended March 31, 2025, before the U.S. market opens on May 19, 2025.

The management team of Gamehaus will host a conference call at 08:00 A.M. Eastern Time on Monday, May 19, 2025 (08:00 P.M. Beijing/Hong Kong time on the same day) to discuss the financial results. In advance of the conference call, all participants must use the following link to complete the online registration process. Upon registering, each participant will receive access details for this conference including a conference passcode, a unique PIN number (personal access code), dial-in numbers, and an e-mail with detailed instructions to join the conference call.

Participant Online Registration: https://dpregister.com/sreg/10199786/ff24367338

A live and archived webcast of the conference call will be available on the Company’s Investor Relations website at https://ir.gamehaus.com/.

About Gamehaus

Gamehaus Holdings Inc. is a technology-driven mobile game publisher dedicated to nurturing partnerships with small- and medium-sized game developers to amplify their success. “You make successful games. We make games successful” is the company’s mantra, encapsulating its commitment to transforming potential into prosperity through data-driven monetization support and optimizing game publishing solutions. For more information, please visit https://ir.gamehaus.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s most recent filings with the U.S. Securities and Exchange Commission.

Investor Relations Contact
Gamehaus Holdings Inc.
Investor Relations Team
Email: IR@Gamehaus.com 

The Blueshirt Group
Mr. Jack Wang
Email: Gamehaus@TheBlueshirtGroup.co 

View original content:https://www.prnewswire.com/news-releases/gamehaus-holdings-inc-to-announce-interim-financial-results-for-the-first-nine-months-of-fiscal-2025-on-may-19-2025-302455120.html

SOURCE Gamehaus Holdings Inc.

Continue Reading

Technology

Bridge to Life Announces Abstract Presentations at The 2025 International Congress of the International Liver Transplantation Society (ILTS) in Singapore, May 28-31, 2025

Published

on

By

Abstracts to highlight hypothermic oxygenated perfusion (HOPE) in liver transplants, including pediatric patients

CHICAGO, May 15, 2025 /PRNewswire/ — Bridge to Life™ Ltd., a leader in organ preservation solutions and perfusion technology, today announced the presentation of nine accepted abstracts, including two late-breakers, at the 2025 International Congress of the International Liver Transplantation Society (ILTS). The conference is scheduled to take place in Singapore, from May 28-31, 2025.

Abstracts to be presented:

Late Breaker: Impact of Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation: A Donor Age-Stratified Analysis, Marco Maria Pascale, Francesco Frongillo, Giorgia Selvaggi, Giuseppe Bianco, Anna Caltabellotta, Erida Nure, Salvatore Agnes, Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy

Late Breaker: Machine Perfusion in Liver Transplantation: A Game Changer for Middle-Volume Centers?, Marco Maria Pascale, Francesco Frongillo, Giorgia Selvaggi, Giuseppe Bianco, Anna Caltabellotta, Erida Nure, Salvatore Agnes, Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy

Use of HOPE Machine Perfusion for Transplantation in Unusual Scenarios – A Case Report, Alba Bueno, Chris Neophytou, George Clarke, Keith Roberts, Khalid Sharif, Rebeca S. Mateos, Hector Vilca-Melendez, Liver Units, Birmingham Children’s Hospital and Queen Elizabeth Hospital, Birmingham, United Kingdom

Hypothermic Oxygenated Perfusion (HOPE) in Pediatric Liver Transplantation: Preliminary Results, Ane Andrés, María Velayos, Javier Serradilla Rodríguez, Alba Sánchez-Galán, José Luis Encinas, Paula Burgos, Iñigo Velasco, Jorge Utanda, Esteban Frauca y Francisco Hernandez-Oliveros, Hospital Universitario La Paz, Madrid, Spain

HOPE for Hepatocellular Carcinoma – Recurrence Analysis in Patients Transplanted with Grafts Submitted to Hypothermic Oxygenated Perfusion, Maria João Amaral; Mariana Duque; Júlio Constantino; Pedro Oliveira; João Simões; Ricardo Martins; António Pinho; Emanuel Furtado; José Guilherme Tralhão; Dulce Diogo, Coimbra University Hospital Centre, Coimbra, Portugal

The Impact of HOPE on Liver Transplantation for ACLF and ALF: A Promising Perspective, Pedro Pinto, Mariana Lobo, Andreia Matos, Pedro Oliveira, Dulce Diogo, José Tralhão; Coimbra University Hospital Centre, Coimbra, Portugal

Results of Implementation of Hypothermic Oxygenated Perfusion (HOPE) for Human Liver Grafts before transplantation in a Tertiary Hospital, Andrea González De Godos, Francisco Javier Tejero Pintor, Martín Bailón Cuadrado, José Carlos Sarmentero Prieto, Pilar Pinto Fuentes, Enrique Asensio Diaz, Paloma Lourdes Rodríguez Vielba, Fernando Labarga Rodríguez, David Pacheco Sánchez, Hospital Universitario Rio Hortega, Valladolid, Spain

HOPE for combined Heart and Liver Transplant, Mireia Caralt, José Andrés Molino, Jesús Quintero, Núria Montferrer, Joan Balcells, Cristina Padrós, Maria Margaret Mercadal, Raul Feline Abella,Ferran Gran, Ernest Hidalgo, Hospital Universitari Vall d’Hebron, Barcelona, Spain

HOPE for the hopeless grafts. Experience from a single center, Mireia Caralt, Laura Vidal, Sandra Torres, José Andrés Molino, Marta Martos, Piero Alberti, Cristina Dopazo, Concepción Gómez, Itxarone Bilbao, Ramon Charco, Ernest Hidalgo, , Hospital Universitari Vall d’Hebron, Barcelona, Spain

In addition to the abstract presentations, Bridge to Life will also be participating in the Hands-On Liver Machine Perfusion Workshop taking place on May 28, 2025.  Separate registration is required: 5th ILTS Hands-on Liver Machine Perfusion Workshop – ILTS Congress 2025

Bridge to Life will also be sponsoring a symposium on May 29 at 3:00 pm SST (UTC+8) on “Expanding the Boundaries of Hypothermic Oxygenated Perfusion: Addressing Challenges and Opportunities in the Asia-Pacific Region”.  Speakers include Dr. Sonal Asthana from Aster Hospitals, Dr. Andrea Schlegel from Cleveland Clinic, Ohio and Dr. Rebeca Sanabria Mateos from Queen Elizabeth Hospital, Birmingham.

About Bridge to Life Ltd

Bridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW®, EasiSlush® and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally.

1 VitaSmart is CE Marked and available for sale in several markets outside of the United States. VitaSmart is not approved for sale in the US.

Logo – https://mma.prnewswire.com/media/2085277/Bridge_to_Life_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/bridge-to-life-announces-abstract-presentations-at-the-2025-international-congress-of-the-international-liver-transplantation-society-ilts-in-singapore-may-28-31-2025-302455913.html

Continue Reading

Technology

Athean Launches with New AI-Powered Sales Platform to Supercharge Prospecting

Published

on

By

SAN FRANCISCO, May 15, 2025 /PRNewswire/ — Athean, a new AI-driven prospecting and engagement platform, launches today to transform how sales teams win deals. Designed to eliminate tool overload and data silos, Athean centralizes the entire sales ecosystem into one intelligent platform. By streamlining workflows and surfacing actionable insights, Athean supercharges prospecting, enabling teams to easily find and meaningfully engage with high-quality prospects.

“Sales reps are inundated with countless tools for prospecting, valuable data is siloed, and time is lost in the endless switching between platforms,” said John Kim, Co-founder and CEO of Athean. “We created Athean to fill a critical void in the sales technology marketplace – a tool thoughtfully designed to help sales teams deploy their skills more effectively and close better deals faster.”

Athean unifies sales data and tools that reps use daily – from CRMs and prospect databases to communication history – into a single platform, and its AI models arm reps with actionable insights into their accounts. Sales engagement, including calls, emails, and sequences, can also be managed directly in Athean. This seamless access to information enables teams to spend less time gathering data and more time connecting with potential customers.

“Athean isn’t just another prospecting tool; it’s a precise, powerful solution created with the explicit goal of helping individuals master the sales process,” said Kim. “Our intelligent platform provides salespeople with detailed, prioritized insights into their prospect pipeline – who to contact, when, and why – so that they can spend their time on what actually moves deals forward: building relationships.”

Key benefits highlighted in early customer experiences include:

Context: With deep insights into prospects, Athean shines a light on the contacts and context sales teams need to connect meaningfully and efficiently with the right prospects, at the right time.Clarity: Simplified, impactful data presentation integrates seamlessly with your existing tech stack which means less tools and fewer tabs, eliminating the distraction and chaos of prospecting to give sales reps clarity and focus.Connection: We estimate Athean can free up as much as two hours every day, allowing reps to do what they do best: building genuine, lasting relationships.

Athean was originally designed at Silicon Valley security company, Verkada, to be used by their 1,000+ person sales team. Athean will operate as an independent venture of Verkada and is now publicly available to sales teams eager to elevate their prospecting efforts. Learn more at Athean.com.

About Athean
Athean is an AI-driven prospecting and engagement platform that unifies customer and prospect data, communications history, and market signals to transform how sales teams win deals. Athean’s AI-powered tools eliminate tab-switching and manual validation, helping sales reps to identify high potential accounts, surface relevant intel and engage with enriched prospect data – arming your team with the contextual knowledge that builds instant credibility. The result: better conversations, more qualified opportunities, and ultimately, more closed revenue. For more information, please visit www.athean.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/athean-launches-with-new-ai-powered-sales-platform-to-supercharge-prospecting-302456043.html

SOURCE Athean

Continue Reading

Trending